

# Ultrafast Optofluidic Imaging on a Chip for Massive Image-based Single-cell Profiling

T.-H. Xiao<sup>1, 2, 3</sup>

<sup>1</sup>Henan Key Laboratory of Diamond Optoelectronic Materials and Devices  
School of Physics and Microelectronics, Zhengzhou University  
Zhengzhou, 450052, China

<sup>2</sup>Institute of Quantum Materials and Physics, Henan Academy of Sciences, Zhengzhou 450046, China

<sup>3</sup>Department of Chemistry, The University of Tokyo, Tokyo 113-0033, Japan

**Abstract**— Ultrafast optofluidic imaging is an emerging interdisciplinary technology that seamlessly integrates ultrafast optical imaging with microfluidics, which is capable of realizing high-resolution, high-throughput, high-content imaging and quantitative analysis of biological organisms in high-speed and complex fluid environments. Ultrafast optofluidic imaging has exhibited promising application potential in bioenergy, food science, drug screening, disease diagnosis and many other fields. In this talk, I will review our recent research progress on ultrafast optofluidic imaging on a chip for massive image-based single-cell profiling. Specifically, we developed several methods, including time-stretch brightfield imaging, time-stretch quantitative phase imaging, frequency division multiplexing imaging, to statistically identify and characterize various blood cells on a chip. By virtue of the high throughput above 10,000 cells per second and the high spatial resolution of 800 nm, we were able to apply our methods for practical biomedical applications [1–5]. First, we utilized our method for characterizing the landscape of circulating platelet aggregates and temporally monitoring blood cells in patients with COVID-19 [1]. The analysis of the big image data shows the anomalous presence of excessive platelet aggregates in nearly 90% of COVID-19 patients. Second, we used our method to study the long-term effects of mRNA COVID-19 vaccinations on platelets [2]. Our result shows no significant or persisting platelet aggregation trends following the vaccine doses. Third, we combined our method with an *in vitro* 3D stenosis microfluidic chip to study stenosis-induced platelet aggregation and efficacy of antiplatelet drugs on atherosclerosis [3, 4]. Our method shows practical utility for development of optimal pharmacologic strategies for patients with atherosclerosis. Our ultrafast optofluidic imaging on a chip is expected to provide a powerful tool for cell biology and medicine.

## REFERENCES

1. Nishikawa, M., H. Kanno, Y. Zhou, T.-H. Xiao, T. Suzuki, Y. Ibayashi, J. Harmon, S. Takizawa, K. Hiramatsu, N. Nitta, R. Kameyama, W. Peterson, J. Takiguchi, M. Shifat-E-Rabbi, Y. Zhuang, X. Yin, A. H. M. Rubaiyat, Y. Deng, H. Zhang, S. Miyata, G. K. Rohde, W. Iwasaki, Y. Yatomi, and K. Goda, “Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19,” *Nature Communications*, Vol. 12, 7135, 2021.
2. Zhou, Y., M. Nishikawa, H. Kanno, R. Yang, Y. Ibayashi, T.-H. Xiao, W. Peterson, M. Herbig, N. Nitta, S. Miyata, Y. Kanthi, G. K. Rohde, K. Moriya, Y. Yatomi, and K. Goda, “Long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets,” *Cytometry Part A*, Vol. 103, 162, 2023.
3. Deng, Y., J. A. Duque, C. Su, Y. Zhou, M. Nishikawa, T.-H. Xiao, Y. Yatomi, H. W. Hou, and K. Goda, “Understanding stenosis-induced platelet aggregation on a chip by high-speed optical imaging,” *Sensors and Actuators B: Chemical.*, Vol. 356, 131318, 2022.
4. Deng, Y., H. M. Tay, Y. Zhou, X. Fei, X. Tang, M. Nishikawa, Y. Yatomi, H. Hou, T.-H. Xiao, and K. Goda, “Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip,” *Lab on a Chip*, Vol. 23, 410, 2023.
5. Xiao, T.-H., Y. Zhou, and K. Goda, “Unlocking the secrets of the invisible world: Incredible deep optical imaging through in-silico clearing,” *Light Science & Applications*, Vol. 12, 161, 2023.